1-Ethyl-1-phenethylbiguanid | 102950-36-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-Ethyl-1-phenethylbiguanid
• 英文别名: 1-ethyl-1-phenethyl-biguanide；1-Aethyl-1-phenaethyl-biguanid；3-(Diaminomethylidene)-1-ethyl-1-(2-phenylethyl)guanidine
• CAS: 102950-36-7
• 化学式: C₁₂H₁₉N₅
• 分子量: 233.316
• InChiKey: PIJVIUVOJMPMFC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  91.5
• 氢给体数：
  3
• 氢受体数：
  1

文献信息

• Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
  申请人：Gedulin Bronislava

  公开号：US10188646B2

  公开（公告）日：2019-01-29

  Provided herein are methods of utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents for the treatment of obesity, diabetes, and inflammatory gastrointestinal conditions.

  本文提供了利用胆汁酸转运抑制剂和/或肠内分泌肽增强剂治疗肥胖症、糖尿病和炎症性胃肠病的方法。
• Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
  申请人：Lumena Pharmaceuticals LLC

  公开号：US10512657B2

  公开（公告）日：2019-12-24

  Provided herein are methods of treating or ameliorating a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a pediatric liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof.

  本文提供了治疗或改善小儿胆汁淤积性肝病的方法，其方法是向有需要的个体非系统地施用治疗有效量的儿科制剂，该制剂包含尖端钠依赖性胆汁酸转运体抑制剂（ASBTI）或其药学上可接受的盐。还提供了治疗或改善小儿肝病、降低血清胆汁酸或肝胆汁酸水平、治疗或改善瘙痒症、降低肝酶或胆红素的方法，包括向有需要的个体非系统地施用治疗有效量的包含ASBTI或其药学上可接受的盐的儿科制剂。
• BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF HYPERCHOLEMIA AND CHOLESTATIC LIVER DISEASE
  申请人：Lumena Pharmaceuticals LLC

  公开号：US20200207797A1

  公开（公告）日：2020-07-02

  Provided herein are methods of treating or ameliorating hypercholemia or a cholestatic liver disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising administering to an individual in need thereof a therapeutically effective amount of ASBTI or a pharmaceutically acceptable salt thereof.
• BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES
  申请人：Lumena Pharmaceuticals LLC

  公开号：US20200246366A1

  公开（公告）日：2020-08-06

  Provided herein are methods of treating or ameliorating a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a pediatric liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof.
• BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS
  申请人：Satiogen Pharmaceuticals, Inc.

  公开号：US20220362238A1

  公开（公告）日：2022-11-17

  Provided herein are methods of utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents for the treatment of obesity, diabetes, and inflammatory gastrointestinal conditions.